Compare Expeditors International of Wshngtn Inc (EXPD) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs Sanofi SA — how do they compare? Expeditors International of Wshngtn Inc trades at $177.4 (market cap $23.04B), while Sanofi SA trades at $43.51 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 4.5× Expeditors International of Wshngtn Inc's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| EXPD | SNY | |
|---|---|---|
Market Cap | $23.04B | $104.30B |
Sector | Industrials | Health |
52-Week High | $182.80 | $52.34 |
52-Week Low | $113.13 | $41.33 |
Enterprise Value | $22.57B | $124.19B |
Dividend Yield | 0.91% | 5.55% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
